(Press-News.org) Researchers are beginning to explore whether the genetics of patients who experience a placebo effect are different from those of patients who don't. It's well known that people can feel better if they believe they are receiving treatment, but the biological pathways involved are relatively unexplored. In a new review, publishing April 13 in Trends in Molecular Medicine, scientists at Beth Israel Deaconess Medical Center discuss what we know as well as possible ethical issues related to conducting genetic tests to determine whether a patient is a placebo responder.
"Understanding the placebome--the collection of genes related to placebo responses--opens possibilities to improving patients' responses to clinical care and pharmaceuticals and to refining research designs for detecting drug-placebo differences," says lead author Kathryn Hall, PhD, a member of Beth Israel Deaconess Medical Center's Program in Placebo Studies.
Past studies have revealed that certain signaling pathways in the brain--especially the dopamine, opioid, endocannabinoid, and serotonin pathways--help mediate the placebo effect. Hall and her colleagues examined evidence that genetic variations in these pathways can modify the placebo effect; their findings raise the possibility of using genetic screens to identify placebo responders. Such information could lead to better patient selection for clinical trials--for example by pointing to those who should be excluded because they are likely to experience a benefit no matter what treatment they receive or by ensuring that potential placebo responders are evenly allocated across treatment arms.
Hall notes that if the placebo response is influenced by certain brain signaling pathways, then it might also affect patients' responses to drugs that target those same pathways, and the magnitude of the drug effect might differ from one patient to another as a result of their genotype.
"These are novel hypotheses that, to our knowledge, have not yet been discussed in the scientific literature," she says. "This broader conception that points to more personalized medicine calls for additional research." Her group proposes including no-treatment controls in addition to placebo controls in some future clinical trials. "Our proposal to incorporate a formal placebo study into future clinical trials is innovative and could represent significant cost savings, leading to rapid access to knowledge of mechanisms involved in the placebo response across a wide variety of disease and drug regimens," Hall says.
A number of ethical issues must be considered if genetic profiles of placebo responders can be established. If high placebo responders are not included in clinical trials, this raises several important questions. For example, how will the drugs be labeled, and which patients will be approved for treatment in light of the fact that the drugs will have only been tested in placebo non-responders? Should physicians test for genetic placebo-response propensities and should patients be allowed to refuse permission to be tested? Should patients be told about their propensity to respond to placebos, and could patients refuse to know or refuse to have this designation in their medical records? Would physicians be able to ethically use this information and, if so, how? And of course, what if knowing one is a placebo responder affects one's placebo response?
INFORMATION:
This study was funded by the National Institutes of Health and the National Center for Complementary and Integrative Health.
Trends in Molecular Medicine, Hall et al.: "Genetics and the Placebo Effect: the Placebome" http://dx.doi.org/10.1016/j.molmed.2015.02.009
Trends in Molecular Medicine (TMM), published by Cell Press, is a monthly review journal that facilitates communication between groups of highly trained professionals who share the common goal of understanding and explaining the molecular basis of disease as it relates to new clinical practice. For more information, please visit http://www.cell.com/trends/molecular-medicine. To receive media alerts for TMM or other Cell Press journals, please contact press@cell.com.
A new strategy to rule-out and rule-in heart attacks in emergency departments will help physicians treat patients faster, found a clinical trial published in CMAJ (Canadian Medical Association Journal).
Acute myocardial infarction (MI) is a common cause of death and disability around the world. Early diagnosis is critical for treatment and survival.
Swiss and Spanish researchers conducted a clinical trial to determine whether a new technique, previously tested in a small pilot study, would be effective in determining whether a patient has had a heart attack. They enrolled ...
Family physicians have an important role in advising women about the benefits and risks of egg freezing, argues an analysis in CMAJ (Canadian Medical Association Journal).
"With growing public awareness of social egg freezing, Canadian women may increasingly approach physicians in search of information and advice about the procedure," writes Dr. Angel Petropanagos, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, with coauthors Alana Cattapan, Françoise Baylis and Arthur Leader. "Family physicians are uniquely positioned at the front lines of medical ...
Melanoma cells become drug resistant by using surrounding healthy cells to provide a 'safe haven' from treatment, according to new research* published in Cancer Cell today (Monday).
Around half of melanomas are caused by a mutation in a gene called BRAF. Drugs called BRAF inhibitors treat these melanomas by targeting the faulty gene. But these cancers can quickly develop resistance to these targeted treatments.
Scientists at the Francis Crick Institute, funded by Cancer Research UK, and at the Cancer Research UK Manchester Institute have discovered that a side effect ...
A drug with the potential to reverse resistance to immunotherapy has been developed by scientists at the University of Southampton. It has shown great promise in pre-clinical models and will be available to patients with certain leukaemias and non-Hodgkin lymphomas in clinical trials later this year.
Targeted drugs made from engineered immune proteins - called monoclonal antibodies - have revolutionised treatment for several types of cancer in recent years. They work by sticking to specific proteins found on the surface of cancer cells, flagging them up to be killed by ...
BOSTON -Placebos have helped to ease symptoms of illness for centuries and have been a fundamental component of clinical research to test new drug therapies for more than 70 years. But why some people respond to placebos and others do not remains under debate.
With the advent of genomics, researchers are learning that placebo responses are modified by a person's genetics, a discovery that raises important new questions regarding the role of the placebo in patient care and in drug development: How many genetic biomarkers exist? Can the medical field harness the placebo ...
This news release is available in Spanish. Through his latest research, Javier Polavieja, a professor Sociology in the Social Sciences Department who holds a UC3M- Santander Named Chair of (Cátedra de Excelencia), has shown how European women who emigrate to other countries within the same continent take the cultural norms of their home countries with them. Those norms are decisive when it comes to determining their work behavior.
To reach this conclusion, the researcher compared the attitudes of over three thousand immigrant women from some twenty European countries ...
This news release is available in French.
Dancing the Argentine tango could have potential benefits for people at certain stages in the development of Parkinson's disease (PD), according to findings in a new study by researchers at the Montreal Neurological Institute and Hospital -The Neuro, McGill University and the Research Institute of the McGill University Health Centre. The study looked at changes in patients' motor abilities following a 12-week tango course, and is also the first study to assess the effect that tango has on non-motor symptoms.
The study looked ...
A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long-term-care facilities, according to an article published online by JAMA Internal Medicine.
Nearly 2 million frail elderly Americans live in long-term care facilities and many of them have osteoporosis and bone fracture rates higher than less impaired elderly individuals. A hip fracture can be dire, decreasing mobility, independence and often leading to death, according to background in the study.
Susan L. ...
Pediatric readiness at emergency departments (EDs) throughout the United States appears to have improved based on self-reported online assessments of compliance with national guidelines, according to an article published online by JAMA Pediatrics.
The importance of EDs maintaining a state of readiness to care for children cannot be overemphasized because day-to-day readiness affects disaster planning and response and patient safety. The Emergency Nurses Association joined the American Academy of Pediatrics and the American College of Emergency Physicians in cosponsoring ...
BOSTON - Targeted cancer therapies work by blocking a single oncogenic pathway to halt tumor growth. But because cancerous tumors have the unique ability to activate alternative pathways, they are often able to evade these therapies -- and regrow. Moreover, tumors contain a small portion of cancer stem cells that are believed to be responsible for tumor initiation, metastasis and drug resistance. Thus, eradicating cancer stem cells may be critical for achieving long-lasting remission, but there are no drugs available that specifically attack cancer stem cells.
Now a research ...
